.svg){kind=small}
Jun-2026
Sales
Trend
6-Month
Product Count
SKUs
Avg Price
YoY Sales Change
YoY Price Change
Market Insights Snapshot
In June 2026, Ovis operated as a single-category brand in Capsules, with category share at 100.0% and category sales down 54.24% year over year and 21.68% month over month. Average price rose 11.40% YoY to $16.55 while total brand sales fell 54.24% YoY, placing Ovis at rank 10 in Capsules in Alberta. The pattern implies a consolidation strategy that concentrates exposure in Capsules while absorbing volume contraction faster than price can offset it, anchoring positioning to a narrower, price-firming niche.
The mix’s total reliance on Capsules amid a 21.68% MoM decline and a 54.24% YoY drop, alongside an 11.40% YoY price increase, indicates Ovis is trading fewer units at higher prices, which risks further rank pressure from position 10 if elasticity persists. Because share is 100.0% in Capsules and average price climbed while 24‑month sales contracted 69.09%, the brand’s differentiation now hinges on sustaining premium tolerance rather than cross-category resilience; the implication is that Ovis must either deepen Capsule-specific loyalty to defend rank 10 or reintroduce a secondary category to dilute volatility from single-category swings.
Competitive Landscape
Ovis sits at #10 in AB Capsules in June 2026, down 1 rank from #9 year over year, and unchanged versus #10 three months ago, while the brand’s prior peak of #7 in April 2025 marks a 3-position slide since that high; in contrast, Emprise Canada advanced from #4 to #3 alongside a 34.9% YoY sales increase and Stigma Grow fell from #3 to #4 with a 69.6% YoY decline, indicating Ovis’s flat rank quarter-on-quarter and slight YoY erosion place it closer to brands losing share than to climbers, implying a trajectory that risks further drift unless underlying drivers shift.
Notable Products
CBG/CBD/THC 1:1:1 Softgels 15-Pack (75mg CBG, 75mg CBD, 75mg THC) posted the largest movement in June 2026 with a +54.8% month-over-month gain to rank 2, contrasting with THC Softgel 15-Pack (150mg) dropping 42.6% while holding rank 1. Blue THC Softgel 50-Pack (125mg) fell 12.8% to rank 3, and two SKUs tied at rank 5 each declined just over 52%, indicating price-sensitive churn even as the leader maintained the top slot with $4,488. Four of the top six ranks are Capsules from balanced or multi-cannabinoid formulas, implying Ovis is tilting the mix toward ratio and multi-compound softgels to stabilize demand beyond single-cannabinoid THC offerings.
Top Selling Cannabis Brands
Data for this report comes from real-time sales reporting by participating cannabis retailers via their point-of-sale systems, which are linked up with Headset’s business intelligence software. Headset’s data is very reliable, as it comes digitally direct from our partner retailers. However, the potential does exist for misreporting in the instance of duplicates, incorrectly classified products, inaccurate entry of products into point-of-sale systems, or even simple human error at the point of purchase. Thus, there is a slight margin of error to consider. Brands listed on this page are ranked in the top twenty within the market and product category by total retail sales volume.
